Founded in 2017, the ETH Spinoff Scailyte discovers ultrasensitive biomarkers and develops in-vitro diagnostics using single-cell technologies and its proprietary single-cell data analysis platform ScaiVision. The platform offers best-in-class analysis of complex single-cell data to enhance biomedical research, pharmaceutical discovery and precision diagnostics. Besides developing its own in vitro diagnostic (IVD) applications, Scailyte also offers its biomarker discovery services to companies aiming to complement and enrich their analysis by adding the single-cell perspective.
“The current version covers all aspects of processing, handling and interpreting single-cell proteomics data (mass and flow cytometry), as well as a core functionality for analysing single-cell transcriptomics data. This allows us to accelerate biomedical discovery and enable the next generation of precision diagnostics”, said Peter Nestorov, CEO of Scailyte AG.
The recently raised capital from Swisscom Ventures, 4FO Venture and the startup Incubator Hemex will enable Scailyte to further build upon its biomarker and IVD pipeline, and drive the development of the first clinical applications using single-cell biomarkers. Additionally, the startup aims to leverage the support from its partner to further in the fast-emerging Single-Cell Analysis field, enabling various clinical applications of single-cell data as expressed by Nestrorov.
"Since we began supporting Scailyte in 2018 we have been impressed by the team and the positive results. We see an opportunity to leverage their AI technology to build a portfolio of biomarkers which will have a positive effect on the speed of patient diagnosis”, said Dominique Mégret, Head of Swisscom Ventures.
(Press release/RAN)
Please login or sign up to comment.
Commenting guidelines